Fig. 8: NeoPalAna 33-gene signature predicts response to CDK4/6 inhibitors in primary and metastatic ER + HER- breast cancer. | Nature Communications

Fig. 8: NeoPalAna 33-gene signature predicts response to CDK4/6 inhibitors in primary and metastatic ER + HER- breast cancer.

From: Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial

Fig. 8: NeoPalAna 33-gene signature predicts response to CDK4/6 inhibitors in primary and metastatic ER + HER- breast cancer.

A Schematic of discovery and validation cohorts. B 33-gene CDK4/6i resistance signature and annotated canonical, biological function. Bolded genes represent differentially expressed genes from the NeoPalAna ET-R cohort identified through DEseq2 analysis. C PCA of Sensitive and Resistant tumors by baseline gene expression signature in NeoPalAna ET-R (n = 13 Sensitive, 7 Resistant) and D NeoPalAna Initial (n = 26 Sensitive, 5 Resistant) cohorts. E Receiver Operating Characteristic (ROC) curves in NeoPalAna ET-R and F NeoPalAna Initial of baseline Ki67, derived gene signature, and combination. G Kaplan–Meier progression-free survival (PFS) curves by gene signature score in  all treated patients (left panel), those treated with CDK4/6i with aromatase inhibitors (middle panel), and those treated with CDK4/6i with fulvestrant (right panel) in the “Real world” Metastatic cohort. H Overall survival of all treated patients in the Metastatic cohort. Also in (G), HR Hazard Ratio, calculated with Log-Rank test, comparing to the low score cohort, with 95% confidence intervals.

Back to article page